MID ATLANTIC PROSTATE CANCER BANK

前列腺癌是我们这个时代最大的医学挑战之一。在美国，它在绝对发病率上排名第一，仅次于肺癌，是导致男性癌症死亡的原因。直肠指检和血清前列腺特异性抗原筛查（PSA）的日益常规使用提高了公众对前列腺癌的认识、诊断和接受前列腺癌治疗的男性人数。这发生在分子病理学的进步为研究人员提供了更多研究癌症的机会的时候。然而，加强前列腺癌研究的关键是这种恶性肿瘤及其相应的良性和正常肿瘤的标本的现成可用性。本提案的主要目标是建立一个全面的，用户友好的，最先进的数据库，包含最佳保存的前列腺癌，前列腺上皮内肿瘤，良性和正常前列腺组织和生物（血液，尿液等）标本以及相应的临床数据，以协助将基础研究转化为临床应用。具体目标是：建立一个中大西洋前列腺癌银行（MAPCB），由有能力和有兴趣共同努力实现NCI合作前列腺癌组织资源（资源）的创建和目标的机构组成；建立并维护完整的高质量前列腺癌、良性、正常及其他相关细胞、体液标本库，并附有相关临床资料；建立质素保证制度，监察收集和保存资料的过程，并确保收集和分发给个别调查人员的资料的质素；建立一种管理结构，在为研究者提供准确的标本信息和相应的临床数据的同时，维护患者的机密性；回顾有关前列腺癌的新兴研究，以保持保存标本的相关性；并与NCI和其他获奖者合作，宣传资源，优化（和标准化）标本和临床数据收集，保存，质量控制和分发流程和政策。这一资源将确保研究人员将获得最佳的研究标本与临床病理相关性为他们的研究。

Prostate cancer is one of the great medical challenges of our time. It stands first in absolute incidence and second only to lung cancer as a cause of cancer mortality among men in the United States. The increasingly routine use of digital rectal examination and serum prostate-specific antigen screening (PSA) has magnified public awareness, diagnosis, and the number of men undergoing treatment for prostate cancer. This comes at a time when advances in molecular pathology provide researchers expanding opportunities for the study of cancer. However, critical to enhancing research on prostate cancer is the ready availability of specimens of this malignancy and its corresponding benign and normal counterparts. The principal goal of this proposal is to develop a comprehensive, user- friendly, state-of-the-art bank containing optimally preserved specimens of prostate cancer, intraepithelial prostate neoplasms, and benign and normal prostate tissues and biological (blood, urine, etc.) specimens plus their corresponding clinical data in order to assist in the translation of basic research into clinical applications. The specific aims are to: establish a Mid- Atlantic Prostate Cancer Bank (MAPCB) comprised of institutions capable of and interested in working together toward the creation and goals of the NCI Cooperative Prostate Cancer Tissue Resource (Resource); establish and maintain a comprehensive bank of quality fixed and frozen specimens of cancerous, benign and normal prostate and other relevant cell and fluid specimens accompanied by pertinent clinical data; establish a quality assurance system to monitor the collection and preservation processes and ensure the quality of the material collected and distributed to individual investigators; establish an administrative structure to maintain patients' confidentiality while providing investigators accurate information regarding specimens and corresponding clinical data; review emerging research regarding prostate cancer to maintain relevance of banked specimens; and collaborate with the NCI and other awardees to publicize the Resource, optimize (and standardize) specimen and clinical data collection, preservation, quality control, and distribution processes and policies. This resource will assure that investigators will obtain optimal research specimens with clinical-pathologic correlation for their studies.